SCYNEXIS Stock Price, News & Analysis (NASDAQ:SCYX)

$1.85 0.01 (0.54 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$1.85
Today's Range$1.81 - $1.88
52-Week Range$1.52 - $3.72
Volume67,778 shs
Average Volume219,934 shs
Market Capitalization$52.83 million
P/E Ratio-2.28
Dividend YieldN/A
Beta0.36

About SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SCYX
CUSIPN/A
Phone+1-201-8845485

Debt

Debt-to-Equity Ratio0.43%
Current Ratio7.30%
Quick Ratio7.30%

Price-To-Earnings

Trailing P/E Ratio-2.28395061728395
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales203.22
Cash FlowN/A
Price / CashN/A
Book Value$1.45 per share
Price / Book1.28

Profitability

Trailing EPS($0.81)
Net Income$-29,980,000.00
Net Margins-8,569.46%
Return on Equity-64.12%
Return on Assets-37.45%

Miscellaneous

Employees14
Outstanding Shares28,560,000

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) released its earnings results on Tuesday, November, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.03. SCYNEXIS had a negative net margin of 8,569.46% and a negative return on equity of 64.12%. View SCYNEXIS's Earnings History.

Where is SCYNEXIS's stock going? Where will SCYNEXIS's stock price be in 2018?

6 Wall Street analysts have issued 1 year target prices for SCYNEXIS's stock. Their predictions range from $6.00 to $14.00. On average, they expect SCYNEXIS's share price to reach $9.50 in the next year. View Analyst Ratings for SCYNEXIS.

Who are some of SCYNEXIS's key competitors?

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the folowing people:

  • Pamela J. Kirby Ph.D., Chairman of the Board (Age 63)
  • Marco Taglietti M.D., President, Chief Executive Officer, Director (Age 57)
  • Eric S. Francois, Chief Financial Officer
  • Scott A. Sukenick J.D., General Counsel
  • David Angulo M.D., Chief Medical Officer
  • Laurent Arthaud, Director (Age 54)
  • Steven C. Gilman Ph.D., Director (Age 64)
  • Ann F. Hanham Ph.D., Director (Age 62)
  • David C. Hastings, Director
  • Patrick J. Langlois Ph.D., Director (Age 69)

How do I buy SCYNEXIS stock?

Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYNEXIS stock can currently be purchased for approximately $1.85.

How big of a company is SCYNEXIS?

SCYNEXIS has a market capitalization of $52.83 million and generates $260,000.00 in revenue each year. The company earns $-29,980,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. SCYNEXIS employs 14 workers across the globe.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 101 Hudson St Ste 3610, JERSEY CITY, NJ 07302-3978, United States. The company can be reached via phone at +1-201-8845485.


MarketBeat Community Rating for SCYNEXIS (SCYX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SCYNEXIS (NASDAQ:SCYX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.833.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $9.50$9.50$11.00$11.19
Price Target Upside: 419.13% upside419.13% upside562.65% upside514.70% upside

SCYNEXIS (NASDAQ:SCYX) Consensus Price Target History

Price Target History for SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS (NASDAQ:SCYX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/24/2017GuggenheimInitiated CoverageBuy$6.00N/AView Rating Details
8/16/2017HC WainwrightSet Price TargetBuy$14.00HighView Rating Details
8/7/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
5/30/2017AegisReiterated RatingBuyMediumView Rating Details
5/9/2017Needham & Company LLCDowngradeBuy -> HoldHighView Rating Details
3/3/2017Royal Bank of CanadaReiterated RatingOutperform$15.00 -> $11.00N/AView Rating Details
10/7/2016WBB SecuritiesUpgradeBuy -> Strong-Buy$8.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

SCYNEXIS (NASDAQ:SCYX) Earnings History and Estimates Chart

Earnings by Quarter for SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS (NASDAQ SCYX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.30)($0.27)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.16)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.37)($0.21)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.38)($0.35)ViewN/AView Earnings Details
8/8/2016Q216($0.52)($0.56)$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)$0.06 millionViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)$0.06 millionViewN/AView Earnings Details
8/19/2015Q2 2015($0.53)ViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)$5.30 millionViewN/AView Earnings Details
11/13/2014($0.53)($0.45)$4.38 millionViewN/AView Earnings Details
8/13/2014Q2 2014($2.12)ViewN/AView Earnings Details
6/16/2014Q1 2014($21.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

SCYNEXIS (NASDAQ:SCYX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for SCYNEXIS (NASDAQ:SCYX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

SCYNEXIS (NASDAQ SCYX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 30.90%
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)
Institutional Ownership by Quarter for SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS (NASDAQ SCYX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/22/2017Marco TagliettiCEOBuy10,000$2.23$22,300.00303,000View SEC Filing  
8/23/2017Marco TagliettiCEOBuy5,000$1.85$9,250.00287,007View SEC Filing  
8/15/2017Marco TagliettiCEOBuy10,000$1.61$16,100.00287,000View SEC Filing  
8/11/2017Gonzalez David AnguloInsiderBuy10,000$1.55$15,500.0072,000View SEC Filing  
6/21/2017David C HastingsDirectorBuy20,000$1.75$35,000.0020,000View SEC Filing  
5/12/2017Gonzalez David AnguloInsiderBuy15,000$1.70$25,500.0062,000View SEC Filing  
5/12/2017Marco TagliettiCEOBuy25,000$1.69$42,250.00277,000View SEC Filing  
12/21/2016Marco TagliettiCEOBuy25,000$3.30$82,500.00251,000View SEC Filing  
12/16/2016Gonzalez David AnguloInsiderBuy4,000$3.25$13,000.0046,000View SEC Filing  
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.0060,000View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.008,850View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.0015,000View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.0040,000View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00225,000View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.004,225View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04124,754View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00119,000View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00110,500View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00106,000View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07100,000View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.0077,267View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.3652,267View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.0050,000View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

SCYNEXIS (NASDAQ SCYX) News Headlines

Source:
DateHeadline
SCYNEXIS to Participate in the Cantor Antibiotics Summit - PR Newswire (press release)SCYNEXIS to Participate in the Cantor Antibiotics Summit - PR Newswire (press release)
www.prnewswire.com - January 12 at 11:15 AM
SCYNEXIS to Participate in the Cantor Antibiotics SummitSCYNEXIS to Participate in the Cantor Antibiotics Summit
finance.yahoo.com - January 12 at 11:15 AM
SCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from AnalystsSCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 10:22 PM
Celgene (CELG) & SCYNEXIS (SCYX) Critical SurveyCelgene (CELG) & SCYNEXIS (SCYX) Critical Survey
www.americanbankingnews.com - January 9 at 7:08 PM
SCYNEXIS Provides Corporate and SCY-078 Pipeline UpdateSCYNEXIS Provides Corporate and SCY-078 Pipeline Update
finance.yahoo.com - January 5 at 12:22 PM
Comparing SCYNEXIS (SCYX) & Tetraphase Pharmaceuticals (TTPH)Comparing SCYNEXIS (SCYX) & Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - December 27 at 3:54 PM
Financial Analysis: SCYNEXIS (SCYX) and Its CompetitorsFinancial Analysis: SCYNEXIS (SCYX) and Its Competitors
www.americanbankingnews.com - December 26 at 9:21 PM
Head to Head Review: SCYNEXIS (SCYX) versus Its PeersHead to Head Review: SCYNEXIS (SCYX) versus Its Peers
www.americanbankingnews.com - December 19 at 5:22 PM
Contrasting SCYNEXIS (SCYX) & Its RivalsContrasting SCYNEXIS (SCYX) & Its Rivals
www.americanbankingnews.com - December 19 at 11:24 AM
ETFs with exposure to SCYNEXIS, Inc. : December 18, 2017ETFs with exposure to SCYNEXIS, Inc. : December 18, 2017
finance.yahoo.com - December 19 at 11:18 AM
SCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from BrokeragesSCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 5:26 PM
Reviewing SCYNEXIS (SCYX) and Its PeersReviewing SCYNEXIS (SCYX) and Its Peers
www.americanbankingnews.com - December 13 at 9:18 PM
Contrasting SCYNEXIS (SCYX) and Teligent (TLGT)Contrasting SCYNEXIS (SCYX) and Teligent (TLGT)
www.americanbankingnews.com - December 11 at 1:36 PM
SCYNEXIS (SCYX) Rating Increased to Sell at ValuEngineSCYNEXIS (SCYX) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - December 9 at 11:26 AM
Scynexis: This Cash-Rich $2 Biotech Stock Is A Strong Buy Before 2018 - Seeking AlphaScynexis: This Cash-Rich $2 Biotech Stock Is A Strong Buy Before 2018 - Seeking Alpha
seekingalpha.com - December 2 at 8:04 AM
SCYNEXIS (SCYX) Downgraded to Hold at Zacks Investment ResearchSCYNEXIS (SCYX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 2 at 6:22 AM
SCYNEXIS to Participate in Upcoming Investor ConferencesSCYNEXIS to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 28 at 10:54 AM
SCYNEXIS, Inc. (SCYX) Upgraded to "Buy" by Zacks Investment ResearchSCYNEXIS, Inc. (SCYX) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 25 at 12:14 PM
SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare ConferenceSCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 23 at 9:20 AM
SCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from AnalystsSCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 20 at 5:44 PM
SCYNEXIS Appoints Scott Sukenick as General CounselSCYNEXIS Appoints Scott Sukenick as General Counsel
finance.yahoo.com - November 18 at 11:46 AM
ETFs with exposure to SCYNEXIS, Inc. : November 10, 2017ETFs with exposure to SCYNEXIS, Inc. : November 10, 2017
finance.yahoo.com - November 11 at 1:23 PM
SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company UpdateSCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - November 9 at 1:04 PM
Scynexis reports 3Q lossScynexis reports 3Q loss
finance.yahoo.com - November 9 at 1:04 PM
SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 1:04 PM
SCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from BrokeragesSCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 26 at 9:38 PM
Critical Analysis: SCYNEXIS (SCYX) & Akorn (AKRX)Critical Analysis: SCYNEXIS (SCYX) & Akorn (AKRX)
www.americanbankingnews.com - October 17 at 4:10 AM
SCYNEXIS, Inc. (SCYX) Upgraded to Buy at Zacks Investment ResearchSCYNEXIS, Inc. (SCYX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - October 10 at 10:14 AM
In vivo and in vitro data show SCY-078s favorable profile and potential therapeutic benefitIn vivo and in vitro data show SCY-078's favorable profile and potential therapeutic benefit
www.nasdaq.com - October 7 at 8:21 AM
SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
finance.yahoo.com - October 6 at 9:04 AM
SCYNEXIS, Inc. (SCYX) Receives Consensus Recommendation of "Buy" from BrokeragesSCYNEXIS, Inc. (SCYX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 7:16 PM
Contrasting Corium International (CORI) and SCYNEXIS (SCYX)Contrasting Corium International (CORI) and SCYNEXIS (SCYX)
www.americanbankingnews.com - October 1 at 10:22 AM
SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 - NasdaqSCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 - Nasdaq
www.nasdaq.com - September 28 at 12:19 AM
SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
globenewswire.com - September 27 at 5:54 PM
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti Purchases 10,000 SharesSCYNEXIS, Inc. (SCYX) CEO Marco Taglietti Purchases 10,000 Shares
www.americanbankingnews.com - September 25 at 7:36 PM
ETFs with exposure to SCYNEXIS, Inc. : September 22, 2017ETFs with exposure to SCYNEXIS, Inc. : September 22, 2017
finance.yahoo.com - September 23 at 5:44 AM
SCYNEXIS (SCYX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowSCYNEXIS (SCYX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 9:51 AM
What Does SCYNEXIS Inc’s (SCYX) Share Price Indicate?What Does SCYNEXIS Inc’s (SCYX) Share Price Indicate?
finance.yahoo.com - September 14 at 9:51 AM
ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM
ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM
SCYNEXIS to Present at Upcoming Investor ConferencesSCYNEXIS to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 9:49 AM
SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:23 AM
Scynexis Q2 - Steady As She Goes - Seeking AlphaScynexis Q2 - Steady As She Goes - Seeking Alpha
seekingalpha.com - August 23 at 11:22 AM
Insider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of StockInsider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:24 AM
SCYNEXIS, Inc. (SCYX) Given a $14.00 Price Target by HC Wainwright AnalystsSCYNEXIS, Inc. (SCYX) Given a $14.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 16 at 8:02 AM
“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease ... - GlobeNewswire (press release)“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 4:26 PM
“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
finance.yahoo.com - August 15 at 4:26 PM
SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis ... - GlobeNewswire (press release)SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 6:49 AM
SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual MeetingSCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
finance.yahoo.com - August 15 at 6:49 AM
SCYNEXIS, Inc. (NASDAQ:SCYX) Insider Gonzalez David Angulo Purchases 10,000 SharesSCYNEXIS, Inc. (NASDAQ:SCYX) Insider Gonzalez David Angulo Purchases 10,000 Shares
www.americanbankingnews.com - August 15 at 12:16 AM

SEC Filings

SCYNEXIS (NASDAQ:SCYX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

SCYNEXIS (NASDAQ:SCYX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

SCYNEXIS (NASDAQ SCYX) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.